# Fennec Pharmaceuticals Inc. (FENC)

> Source: Nexqual · https://nexqual.com/FENC · data as of 2026-11-18 20:50 UTC · cite as "Nexqual, Fennec Pharmaceuticals Inc. (FENC), nexqual.com/FENC" · informational, not investment advice.

**Price:** USD 13.32 (-1.91% today) · US market open, as of November 18, 2026 at 20:50 UTC; quotes may be delayed. Prev close 13.58 · day 13.04–13.85 · 52w 5.65–13.85 · market cap $470M · NCM

## Key facts
- Last four reported quarters (through Sep 30, 2026): revenue $66.4M, net income $2.0M (3.1% margin) (SEC filings).
- Insider open-market sales, last ~7 months: 9 Form 4 filings, $1.9M; 1 not under a Rule 10b5-1 plan ($146K); 0 by opportunistic insiders, 5 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Total return with dividends: 1Y +52.7% vs S&P 500 +11.9%; 5Y +36.0% vs S&P 500 +66.7%.
- Latest earnings report: 2026-11-12 (next date not yet announced).
- Dividend: FENC paid no cash dividend in the last five years.
- Short interest: 1.49% of float (as of 2026-10-30), 3.6 days to cover.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | — | $1.5M | $21.3M | $47.5M | $44.6M | $66.4M |
| Gross profit | — | $1.4M | $20.0M | — | — | — |
| Operating income | -$17.2M | -$22.6M | -$12.8M | $2.6M | -$6.3M | $3.7M |
| Net income | -$17.3M | -$23.7M | -$16.0M | -$436K | -$9.7M | $2.0M |
| EPS (diluted) | -$0.67 | -$0.90 | -$0.60 | -$0.02 | -$0.34 | — |
| Gross margin | — | 94.4% | 94.1% | — | — | — |
| Operating margin | — | -1471.6% | -60.1% | 5.4% | -14.1% | 5.6% |
| Net margin | — | -1544.9% | -75.5% | -0.9% | -21.8% | 3.1% |
| Revenue growth | — | — | +1284.5% | +123.7% | -6.1% | — |
| Cash + short-term investments | $21.1M | $23.8M | $13.3M | $26.6M | $36.8M | — |
| Total debt | $5.0M | $24.9M | $30.9M | $19.3M | — | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Sep 30, 2026)


## Insider sales (SEC Form 4, open-market, last ~7 months)
8 of 9 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-11-13 | Brughera Marco Maria | Director | 20,000 | $240K | 100% | Yes (adopted June 16, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-09-15 | Brughera Marco Maria | Director | 15,545 | $160K | 100% | Yes (adopted June 16, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-09-01 | Raykov Rosty |  | 10,000 | $121K | 7.4% | Yes | Routine (sold in Nov & Dec each year 2023–2025; this trade is outside those months) |
| 2026-08-31 | Sayad Pierre Sargis | Chief Medical Officer | 12,000 | $146K | 55.8% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-27 | Andrade Robert | CHIEF FINANCIAL OFFICER | 75,000 | $884K | 23.8% | Yes (adopted May 22, 2026) | Too little history (no open-market trades in 2025) |
| 2026-08-03 | Raykov Rosty |  | 10,000 | $96K | 7.1% | Yes | Routine (sold in Nov & Dec each year 2023–2025; this trade is outside those months) |
| 2026-07-01 | Raykov Rosty |  | 9,599 | $100K | 6.5% | Yes (adopted September 19, 2025) | Routine (sold in Nov & Dec each year 2023–2025; this trade is outside those months) |
| 2026-06-01 | Raykov Rosty | Director | 9,747 | $94K | 7% | Yes (adopted September 19, 2025) | Routine (sold in Nov & Dec each year 2023–2025; this trade is outside those months) |
| 2026-05-11 | Rallis Chris A | Director | 8,346 | $59K | 11.7% | Yes | Routine (sold in Jul each year 2023–2025; this trade is outside those months) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-09 | HC Wainwright & Co. | Reiterated | Buy | $16 |
| 2026-08-12 | B. Riley Securities | Target raised | Buy | $16 → $18 |
| 2026-08-12 | Wedbush | Target raised | Outperform | $13 → $16 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-11-18) | 5Y (from 2021-11-15) |
|---|---|---|
| Total return | +52.7% | +36.0% |
| S&P 500 (SPY) | +11.9% | +66.7% |
| Per year | +52.7% | +6.3% |
| Volatility (annualized) | 66.0% | 62.1% |
| Max drawdown | -35.8% (Feb 2026→Mar 2026) | -64.4% (Dec 2023→Nov 2024) |

## Dividends
FENC paid no cash dividend in the last five years.

## Short interest
454,453 shares sold short, 1.49% of the float, as of Oct 30, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 30, 2026): 513,287 shares (-11.5%). Days to cover: 3.6 (short shares ÷ average daily volume).

## Peers (Biotechnology)
KOD (Kodiak Sciences Inc) USD 97.7 +0.93% · BLTE (Belite Bio, Inc) USD 156.45 -0.81% · IBRX (ImmunityBio, Inc.) USD 6.7 +6.95% · ORKA (Oruka Therapeutics, Inc.) USD 95.68 -0.67% · IMVT (Immunovant, Inc.) USD 33.24 +0.08% · CGON (CG Oncology, Inc.) USD 79.85 +1.15%

## More
Full page: https://nexqual.com/FENC · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in FENC's own 10-K filed 2026-03-27 (https://www.sec.gov/Archives/edgar/data/1211583/000110465926036182/fencf-20251231x10k.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Norgine Pharma UK | "In March 2024, we announced that we entered into an agreement with Norgine, a leading European specialist pharmaceutical company." |

## Revenue by product line (quarter ended 2026-09-30)

| Line | Revenue | Share | YoY |
|---|---|---|---|
| Manufactured Product Other | $19.4M | 99.1% | +55.9% |
| Service Other | $183,000 | 0.9% | — |
| Total revenue | $19.6M | 100% | — |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-12-31) | $0.18 | $0.14 | +23.6% | $22.0M | 5 |
| Next quarter (ends 2027-03-31) | $0.14 | $0.11 | +30.3% | $22.9M | 3 |
| Current fiscal year (ends 2026-12-31) | $0.39 | $0.33 | +17.4% | $74.6M | 5 |
| Next fiscal year (ends 2027-12-31) | $1.05 | $0.95 | +10.3% | $107.8M | 5 |

## Options: expected move (Cboe, 15-min delayed)

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 2 | 348.7% | ±25.4% |
| 2027-02-19 | 93 | 99.1% | ±42.6% |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Mar 24, 2026 | Quarter ended Dec 31, 2025 | −$0.10 | $0.04 | Miss −$0.14 | -17.2% |
| Mar 10, 2025 | — | — | — | — | -7.0% |
| Mar 25, 2024 | — | — | — | — | +0.8% |
| Nov 7, 2023 | — | — | — | — | -4.3% |
| Aug 4, 2023 | — | — | — | — | +1.4% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-11-16 | Schedule 13G/A | Solas Capital Management, LLC, FREDERICK TUCKER GOLDEN: 4.1% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1211583/000160486726000020/0001604867-26-000020-index.htm |
| 2026-11-16 | Schedule 13G/A | Sonic Fund II, L.P., Sonic GP LLC: 4.5% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1211583/000101359426001189/0001013594-26-001189-index.htm |
| 2026-11-12 | 10-Q | Quarterly report · period ended Sep 30, 2026 | https://www.sec.gov/Archives/edgar/data/1211583/000110465926126203/0001104659-26-126203-index.htm |
| 2026-10-19 | Schedule 13G/A | Orin Hirschman, AIGH Capital Management LLC: 7.1% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1211583/000149315226047509/0001493152-26-047509-index.htm |
| 2026-09-17 | 8-K | Other material event — “On September 17, 2026, Fennec Pharmaceuticals Inc. (the "Company") announced positive results from the investigator-initiated Phase 2 STS-J01 clinical study of PEDMARK in Japan, which met its primary endpoint and demonstrated significant hearing protection without evidence of interference with cisplatin antitumor activity. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 8.01, including Exhibit 99.1 attached hereto, shall not be…” | https://www.sec.gov/Archives/edgar/data/1211583/000110465926108565/0001104659-26-108565-index.htm |
| 2026-08-14 | Schedule 13G/A | Southpoint Master Fund, LP, Southpoint Capital Advisors LP: 0.0% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1211583/000101297526000770/0001012975-26-000770-index.htm |
| 2026-08-14 | Schedule 13G/A | Solas Capital Management, LLC, FREDERICK TUCKER GOLDEN: 5.4% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1211583/000160486726000013/0001604867-26-000013-index.htm |
| 2026-08-13 | 10-Q | Quarterly report · period ended Jun 30, 2026 | https://www.sec.gov/Archives/edgar/data/1211583/000110465926095884/0001104659-26-095884-index.htm |
| 2026-08-13 | Schedule 13G/A | Rosalind Advisors, Inc., SALAMON STEVEN A J: 9.6% of shares, passive 5%+ holder (amended) | https://www.sec.gov/Archives/edgar/data/1211583/000162262726000020/0001622627-26-000020-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.
